View our free, on-demand webinar

Fusion-based biomarkers are becoming more and more important in precision oncology clinical research, and there is an ongoing discussion regarding the best method of detection. This webinar focuses on next-generation sequencing (NGS) as a method. Most fusions studied in cancer research involve the same known driver genes and partners rather than novel fusions. These can be present in very low levels or the sample can be very limited in tumor content. Therefore, sensitivity and LOD are important for fusion detection. Ease of use, turnaround time, and the bioinformatics pipeline are other critical components.

During this webinar we will:
  • Review three different methods in a comparison study performed and presented by Dr. Wei Song
  • Hear about the principles of and first data generated by a new FusionSync method from Dr. Philip Jermann
  • Discuss the importance of detecting both novel fusions and known driver genes and partners


Dr. Wei Song, MD,PhD

Dr. Wei Song, MD, PhD
Director of the Clinical Genomic Laboratory at the Englander Institute for Precision Medicine
Assistant Professor of Pathology and Laboratory Medicine at Weill Cornell Medical College
Assistant Attending Pathologist at the New York-Presbyterian Hospital

Dr. Philip Jermann, PhD

Dr. Philip Jermann, PhD
Head of Molecular Assay Development Unit at the Institute of Medical Genetics and Pathology, University Hospital Basel, Switzerland

Fill in the form to view the free on-demand webinar.

(*Indicates a mandatory field)